Key Takeaways:
- 1. The RIO trial showed antibodies may impact dormant HIV in cells, potentially helping T cells recognize and kill infected cells.
- 2. The FRESH intervention combines antibodies with a drug to target stubborn HIV reservoirs more directly.
- 3. Further trials in South Africa and the UK will explore enhancing immune responses and long-lasting effects of antibodies in treating HIV.
The RIO trial demonstrated that antibodies could influence dormant HIV cells, offering hope for better treatment outcomes. The FRESH intervention incorporates a drug to target HIV reservoirs directly. Ongoing trials in South Africa and the UK aim to enhance immune responses and the lasting impact of antibodies in managing HIV.
Insight: Combining different approaches, such as stimulating T cells and antibodies, may hold the key to improving HIV treatment efficacy and immune responses.
This article was curated by memoment.jp from the feed source: Ars Technica.
Read the original article here: https://arstechnica.com/science/2025/11/achieving-lasting-remission-for-hiv/
© All rights belong to the original publisher.
